Tanstrive 40mg Tablet may be prescribed for cancers with specific RET (rearranged during transfection) gene alterations, including:

• RET fusion-positive non-small cell lung cancer: For eligible patients with locally advanced or metastatic disease.

• RET-mutant medullary thyroid cancer: For patients with advanced or metastatic disease requiring systemic treatment.

• RET fusion-positive thyroid cancer: For selected advanced or metastatic disease.

• Other RET fusion-positive solid tumours: In eligible patients whose disease has progressed after prior systemic treatment or when there are no satisfactory alternative treatment options.

A validated test is used to identify the relevant RET alteration before treatment.

Tanstrive 40mg Tablet contains Selpercatinib, a RET kinase inhibitor. It blocks abnormal RET signalling involved in the growth and survival of certain cancer cells.

This can slow the growth and spread of RET-driven tumours.

Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins and herbal supplements you take.

• Acid-reducing medicines: Proton pump inhibitors, H2-receptor blockers and antacids can affect Selpercatinib absorption and may require specific timing or adjustment.

• CYP3A inhibitors: Some medicines can increase Selpercatinib levels and may require dose modification.

• CYP3A inducers: These can reduce Selpercatinib levels and should generally be avoided.

• Medicines that prolong QT interval: These may increase the risk of heart rhythm problems.

• CYP2C8, CYP3A and P-glycoprotein substrates: Selpercatinib can affect the levels of certain medicines.

Give your doctor a complete medicine list before starting treatment.

• Store Tanstrive 40mg Tablet according to the storage instructions on the product packaging.

• Keep it in the original pack and protect it from moisture.

• Keep out of reach of children.

Take Tanstrive 40mg Tablet exactly as prescribed by your oncologist.

Selpercatinib is generally taken twice daily, with the dose determined by body weight, cancer type and individual treatment factors. The 40mg tablets may be used together with other strengths to make up the prescribed dose.

Swallow the tablets as directed. Do not change the number of tablets without medical advice.

Common side effects

• Swelling or oedema

• Diarrhoea

• Fatigue

• Dry mouth

• High blood pressure

• Abdominal pain

• Constipation

• Rash

• Nausea

• Headache

Serious side effects

• Liver toxicity

• Interstitial lung disease or pneumonitis

• Severe hypertension

• QT interval prolongation and abnormal heart rhythm

• Serious bleeding

• Severe hypersensitivity reactions

• Tumour lysis syndrome

• Impaired wound healing

Seek medical attention promptly for breathing difficulty, severe weakness, confusion, yellowing of the skin or eyes, severe abdominal pain or new neurological symptoms.

• Have your RET alteration confirmed using an appropriate diagnostic test.

• Attend regular liver function and blood pressure checks.

• Tell your doctor about medicines for acidity or heart rhythm problems.

• Inform your surgeon that you are taking Selpercatinib before planned surgery.

• Report severe diarrhoea, breathing difficulty or unusual bleeding promptly.